1-3 of 3
Jennifer L Beaumont, MS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Assessment of Patient Reported Outcomes (PROs) From the Enestnd Trial with Minimum Follow-up of 36 Cycles.

Jennifer L Beaumont, MS, Matthew Magestro, John Coombs, PharmD, MBA, Xiaolin Fan, PhD, Charisse Kemp, Roger J. Waltzman, MD
Journal: Blood
Blood (2012) 120 (21): 3166.
https://doi.org/10.1182/blood.V120.21.3166.3166
Published: 2012
Journal Articles

Does Baseline Health-Related Quality of Life or Symptom Burden Predict Clinical Outcomes in Patients with Newly Diagnosed CML-CP Treated with Nilotinib or Imatinib?

Jennifer L Beaumont, MS, Cindy Nowinski, MD PhD, John Coombs, PharmD, MBA, Tomasz Szczudlo, Rick E. Blakesley, PhD, Neil J. Gallagher, MD, PhD, James Burns, MS, David Cella, PhD
Journal: Blood
Blood (2011) 118 (21): 1025.
https://doi.org/10.1182/blood.V118.21.1025.1025
Published: 2011
Journal Articles

Hospitalizations of Patients with Newly Diagnosed CML-CP Treated with Nilotinib or Imatinib: Results From a Randomized Phase III Trial

Jennifer L Beaumont, MS*, John Coombs, PharmD, MBA*, amsi Bollu, V, PhD, MBA*, Richard C. Woodman, MD, David Cella, PhD*
Journal: Blood
Blood (2010) 116 (21): 3826.
https://doi.org/10.1182/blood.V116.21.3826.3826
Published: 2010